Nature Reviews Cardiology

(The median citation count of Nature Reviews Cardiology is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-06-01 to 2024-06-01.)
COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives950
Myocarditis and inflammatory cardiomyopathy: current evidence and future directions600
Myocardial ischaemia–reperfusion injury and cardioprotection in perspective599
Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension561
SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control395
Interplay between inflammation and thrombosis in cardiovascular pathology377
Smart wearable devices in cardiovascular care: where we are and how to move forward343
Artificial intelligence-enhanced electrocardiography in cardiovascular disease management334
PPAR control of metabolism and cardiovascular functions333
Global epidemiology of dyslipidaemias324
Endoplasmic reticulum stress and unfolded protein response in cardiovascular diseases295
Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation292
The molecular and metabolic landscape of iron and ferroptosis in cardiovascular disease287
Epidemiology of cardiovascular disease in Europe271
Pathophysiology of sepsis-induced cardiomyopathy267
Global epidemiology of valvular heart disease246
Native and bioengineered extracellular vesicles for cardiovascular therapeutics242
Transportation noise pollution and cardiovascular disease227
Self-powered cardiovascular electronic devices and systems207
Cellular and molecular pathobiology of heart failure with preserved ejection fraction205
Ageing and atherosclerosis: vascular intrinsic and extrinsic factors and potential role of IL-6198
Macrophage-targeted nanomedicine for the diagnosis and treatment of atherosclerosis193
Epicardial adipose tissue in contemporary cardiology191
Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium187
Cardiovascular disease in patients with severe mental illness176
Ceramides and other sphingolipids as drivers of cardiovascular disease169
Epidemiology and management of aortic disease: aortic aneurysms and acute aortic syndromes168
The role of cardiac rehabilitation in improving cardiovascular outcomes167
Heart failure with mid-range or mildly reduced ejection fraction165
Myocarditis after COVID-19 mRNA vaccination: clinical observations and potential mechanisms165
Diabesity: the combined burden of obesity and diabetes on heart disease and the role of imaging152
Systems biology in cardiovascular disease: a multiomics approach145
Therapeutic strategies targeting inflammation and immunity in atherosclerosis: how to proceed?139
Lifestyle interventions for the prevention and treatment of hypertension138
Diffuse myocardial fibrosis: mechanisms, diagnosis and therapeutic approaches135
Next-generation tissue-engineered heart valves with repair, remodelling and regeneration capacity134
Optical coherence tomography in coronary atherosclerosis assessment and intervention133
Epidemiology of the inherited cardiomyopathies130
Sit less and move more for cardiovascular health: emerging insights and opportunities129
Integration of novel monitoring devices with machine learning technology for scalable cardiovascular management120
The quiescent endothelium: signalling pathways regulating organ-specific endothelial normalcy120
Pregnancy and cardiovascular disease115
Genomics of hypertension: the road to precision medicine108
Transforming growth factor-β in myocardial disease103
High-density lipoproteins, reverse cholesterol transport and atherogenesis102
Intracellular calcium leak in heart failure and atrial fibrillation: a unifying mechanism and therapeutic target100
Cardiac optogenetics: a decade of enlightenment99
Apolipoproteins in vascular biology and atherosclerotic disease99
Genomic frontiers in congenital heart disease98
The role of cellular senescence in cardiac disease: basic biology and clinical relevance98
Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development96
Blood pressure and its variability: classic and novel measurement techniques94
Gut-derived low-grade endotoxaemia, atherothrombosis and cardiovascular disease93
Mechanisms and consequences of endothelial cell senescence91
Catheter ablation for atrial fibrillation: current indications and evolving technologies90
Vascular endothelial cell development and diversity86
Complete versus incomplete coronary revascularization: definitions, assessment and outcomes83
Cardiovascular risks of climate change82
Applications of artificial intelligence in cardiovascular imaging82
Climate change and cardiovascular disease: implications for global health81
The role of mitochondrial fission in cardiovascular health and disease77
Cardiac involvement in the long-term implications of COVID-1977
RNA-targeting and gene editing therapies for transthyretin amyloidosis75
Sulfide regulation of cardiovascular function in health and disease74
Epidemiology and prevention of venous thromboembolism74
Update on the pathophysiology and medical treatment of peripheral artery disease74
Bleeding avoidance strategies in percutaneous coronary intervention73
Obesity and the risk of cardiometabolic diseases72
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action72
Branched-chain amino acids in cardiovascular disease71
Myocardial stunning and hibernation revisited71
Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia69
Inflammatory signalling in atrial cardiomyocytes: a novel unifying principle in atrial fibrillation pathophysiology68
Clinical utility of polygenic risk scores for coronary artery disease67
Social determinants of atrial fibrillation67
Epidemiology and modifiable risk factors for atrial fibrillation66
Plaque erosion and acute coronary syndromes: phenotype, molecular characteristics and future directions66
A fresh look at coronary microembolization65
Targeted delivery of therapeutic agents to the heart62
Immune cell profiling in atherosclerosis: role in research and precision medicine59
Prevention of atherosclerosis from childhood57
Interactions between erectile dysfunction, cardiovascular disease and cardiovascular drugs57
Interplay of cardiovascular mediators, oxidative stress and inflammation in liver disease and its complications56
Pharmacogenetics to guide cardiovascular drug therapy55
The evolving cardiac lymphatic vasculature in development, repair and regeneration55
International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia53
Targeting the sarcomere in inherited cardiomyopathies52
Minor hypertrophic cardiomyopathy genes, major insights into the genetics of cardiomyopathies52
Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: a global perspective50
Hallmarks of cardiovascular ageing49
The health digital twin: advancing precision cardiovascular medicine48
Gender medicine: effects of sex and gender on cardiovascular disease manifestation and outcomes47
Non-canonical WNT signalling in cardiovascular disease: mechanisms and therapeutic implications45
Electroimmunology and cardiac arrhythmia45
Non-cardiac surgery in patients with coronary artery disease: risk evaluation and periprocedural management44
SGLT2 inhibitors: role in protective reprogramming of cardiac nutrient transport and metabolism44
Non-canonical features of microRNAs: paradigms emerging from cardiovascular disease41
Macrophages in cardiac remodelling after myocardial infarction41
P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention41
Obstructive sleep apnoea heterogeneity and cardiovascular disease41
Evolving concepts of the vulnerable atherosclerotic plaque and the vulnerable patient: implications for patient care and future research40
Towards precision medicine in heart failure39
Bioengineering approaches to treat the failing heart: from cell biology to 3D printing38
Sirtuins in atherosclerosis: guardians of healthspan and therapeutic targets38
Increasing representation and diversity in cardiovascular clinical trial populations37
Remote monitoring and digital health tools in CVD management37
Stroke prevention strategies in high-risk patients with atrial fibrillation37
The COVID-19 pandemic: a catalyst to improve clinical trials37
Contemporary coronary artery bypass graft surgery and subsequent percutaneous revascularization36
The microtubule cytoskeleton in cardiac mechanics and heart failure35
Cardiovascular risk in diabetes mellitus: epidemiology, assessment and prevention35
The contribution of the exposome to the burden of cardiovascular disease35
The potential of tailoring the gut microbiome to prevent and treat cardiometabolic disease35
The oral microbiome in the pathophysiology of cardiovascular disease34
Coronary vessel formation in development and disease: mechanisms and insights for therapy34
Pulling at the heart: COVID-19, race/ethnicity and ongoing disparities33
Cardio-onco-metabolism: metabolic remodelling in cardiovascular disease and cancer33
Repurposing drugs to treat cardiovascular disease in the era of precision medicine32
Single-cell transcriptomics for the assessment of cardiac disease31
Autonomic dysfunction and postural orthostatic tachycardia syndrome in post-acute COVID-19 syndrome31
Calcific aortic valve disease: mechanisms, prevention and treatment31
Cardiac fibroblasts and mechanosensation in heart development, health and disease31
Mitral valve regurgitation: a disease with a wide spectrum of therapeutic options30
Regression of cardiac hypertrophy in health and disease: mechanisms and therapeutic potential29
Novel and future lipid-modulating therapies for the prevention of cardiovascular disease29
Improving clinical practice guidelines with implementation science29
Hypertension in China: epidemiology and treatment initiatives28
Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiac hypertrophy and heart failure28
Effects of fatty acids on T cell function: role in atherosclerosis28
Temporary mechanical circulatory support devices: practical considerations for all stakeholders28
A change of heart: new roles for cilia in cardiac development and disease27
Changing epidemiology of congenital heart disease: effect on outcomes and quality of care in adults27
Interventional therapies for pulmonary embolism25
Flow-induced reprogramming of endothelial cells in atherosclerosis25
The need for increased pragmatism in cardiovascular clinical trials24
Pathophysiology and risk factors of peripartum cardiomyopathy24
Clinical quantitative coronary artery stenosis and coronary atherosclerosis imaging: a Consensus Statement from the Quantitative Cardiovascular Imaging Study Group24
Reduced hospital admissions for ACS — more collateral damage from COVID-1923
The use of new CRISPR tools in cardiovascular research and medicine23
The role of aldehyde dehydrogenase 2 in cardiovascular disease23
Metabolic mechanisms in physiological and pathological cardiac hypertrophy: new paradigms and challenges23
Plastics and cardiovascular disease22
Neuroimmune axis of cardiovascular control: mechanisms and therapeutic implications22
Genetics and mechanisms of thoracic aortic disease21
The biology of atherosclerosis comes full circle: lessons for conquering cardiovascular disease21
Transcatheter aortic valve implantation in patients with bicuspid valve morphology: a roadmap towards standardization21
Diversity 4.0 in the cardiovascular health-care workforce19
Genomic enhancers in cardiac development and disease18
Cardiovascular health and disease in migrant populations: a call to action18
Long COVID and cardiovascular disease: a learning health system approach18
Developing a vaccine against atherosclerosis18
Clarification of the definition of hypoplastic left heart syndrome18
Current concepts and novel targets for antiplatelet therapy17
Genetics and genomics of arrhythmic risk: current and future strategies to prevent sudden cardiac death16
Global epidemiology of acute coronary syndromes16
A role for lipophagy in atherosclerosis16
PCSK9-targeted therapies: present and future approaches16
The bidirectional association between atrial fibrillation and myocardial infarction16
Current and future applications of virtual reality technology for cardiac interventions15
De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention: a Consensus Statement from an international expert panel on coronary thro15
Trained immunity in atherosclerotic cardiovascular disease15
Clonal haematopoiesis and atherosclerosis: a chicken or egg question?15
RNA modifications in cardiovascular health and disease15
The ongoing quest for the first total artificial heart as destination therapy14
Mechanisms of ryanodine receptor 2 dysfunction in heart failure14
Immune and inflammatory mechanisms in hypertension13
Cardiovascular autonomic dysfunction in post-COVID-19 syndrome: a major health-care burden13
A pathophysiological compass to personalize antianginal drug treatment12
FGF23 and klotho at the intersection of kidney and cardiovascular disease12
The contribution of amyloid deposition in the aortic valve to calcification and aortic stenosis12
The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases12
Nanotherapeutics for cardiovascular disease11
Strategies to prevent burnout in the cardiovascular health-care workforce11
Oxidation of miRNAs by ROS leads to cardiac hypertrophy10
The future of cardiac xenotransplantation10
Travelling with heart failure: risk assessment and practical recommendations9
A cardioimmunologist’s toolkit: genetic tools to dissect immune cells in cardiac disease9
AIMing 2 treat atherosclerosis9
Interplay of hypoxia-inducible factors and oxygen therapy in cardiovascular medicine8
Roadmap on the use of artificial intelligence for imaging of vulnerable atherosclerotic plaque in coronary arteries8
Specialized pro-resolving mediators in vascular inflammation and atherosclerotic cardiovascular disease8
Invention and uptake of TAVI over the first 20 years8
Role of sex hormones in cardiovascular diseases8
ACE2 level as a marker of CVD8
Shaping the future of cardiovascular medicine in the new era of wearable devices8
Cardiovascular health concerns in sexual and gender minority populations8
2023 World Heart Federation guidelines for the echocardiographic diagnosis of rheumatic heart disease8
Heart transplantation: advances in expanding the donor pool and xenotransplantation7
Complexity and plasticity of cardiac cellular composition7
Publisher Correction: Cellular and molecular pathobiology of heart failure with preserved ejection fraction7
Guidelines to lower intake of added sugar are necessary and justified7
Uncertainties about left ventricular thrombus after STEMI7
Myocardial injury in patients with COVID-196
Macrophages and neutrophils modulate arrhythmia risk after myocardial infarction6
Detection of subclinical hypertrophic cardiomyopathy6
A roadmap of strategies to support cardiovascular researchers: from policy to practice6
Circadian medicine: a critical strategy for cardiac care6
Publisher Correction: Reappraising the role of inflammation in heart failure6
Factor XI inhibitors in patients with cardiovascular disease and a high risk of bleeding: a cautionary tale6
Universal flu vaccines: a shot at lifelong cardioprotection?6
Collateral cardiovascular damage during the COVID-19 pandemic6
Cardiac splicing as a diagnostic and therapeutic target6
Very high HDL-C levels are associated with higher mortality in patients with CAD6
Exosome-derived microRNAs improve cardiac function6
The role of cardiac pericytes in health and disease: therapeutic targets for myocardial infarction6
Electron microscopy of cardiac 3D nanodynamics: form, function, future5
Statins promote efferocytosis in atherosclerotic plaques5
Animal models to study cardiac regeneration5
Empagliflozin improves outcomes in HFrEF regardless of diabetic status5
Atherosclerotic plaque stabilization and regression: a review of clinical evidence5
The dynamic cardiac cellular landscape: visualization by molecular imaging5
Programmed death of macrophages in atherosclerosis: mechanisms and therapeutic targets5
Preventing cardiac damage in patients with COVID-195
Lipoprotein(a), platelet function and cardiovascular disease5
A call for training programmes in cardiovascular genomics4
Cardiovascular benefits of fermented foods and beverages: still up for debate4
Caffeine consumption and cardiovascular health4
Effects of lifestyle factors on leukocytes in cardiovascular health and disease4
Piezo1 senses pressure overload and initiates cardiac hypertrophy4
A phoenix rises from the ashes of cardiac cell therapy4
Publisher Correction: Cardiac involvement in the long-term implications of COVID-194
Machine learning predicts risk in ACS4
Oxidized phospholipids in cardiovascular disease4
Clonal haematopoiesis induces a pro-inflammatory monocyte phenotype in HF4
Safety of paclitaxel-coated devices in peripheral artery disease4
Boosting mitochondrial metabolism with dietary supplements in heart failure4
Inclusion of remnant cholesterol improves risk prediction for ischaemic heart disease4
Human susceptibility to coronary artery disease: lessons from chimpanzee resilience4
Exosomes improve myocardial recovery after infarction4
The menopausal transition period and cardiovascular risk4
Promising anti-IL-6 therapy for atherosclerosis4
Cardiovascular physiology and pathophysiology at high altitude4
Diversity in human genetics studies accelerates discovery and improves health care4
Carotid stenosis management: time to address the misconceptions (‘furphies’)4
ERBB2–YAP crosstalk mediates cardiac regeneration in mice3
Reply to ‘Mechanisms of ryanodine receptor 2 dysfunction in heart failure’3
Yoga for the prevention of cardiovascular disease3
Are blood-pressure targets needed to prevent cardiovascular disease?3
Modulating the gut microbiota with dietary interventions to protect against cardiometabolic disease3
Anti-IL-1β therapy lowers leukocyte supply and uptake in atherosclerosis3
Benefits of combination pharmacotherapy for HFrEF3
Empagliflozin improves clinical outcomes for HFpEF in EMPEROR-Preserved3
Sotatercept therapy for PAH3
Lovastatin improves endothelial cell function in LMNA-related DCM3
Maternal cardiovascular disorders before and during pregnancy and offspring cardiovascular risk across the life course3
Targeted therapies for cardiac diseases3
Limited benefit of triglyceride lowering with fibrates in statin-treated patients3
Immunomodulation and immunopharmacology in heart failure3
Hyperglycaemia-induced trained immunity promotes atherosclerosis3
Macrophages promote endothelial-to-mesenchymal transition after MI3